AI Shifts Into the Next (Generative) Gear in Healthcare
Riepilogo
Artificial intelligence (AI) has been transforming health and medicine for several decades, whether through diagnostics, personalized medicine, data analytics or other innovations. The advent of generative AI is now reshaping drug discovery, diagnostics, clinical decisions and delivery of care. Traditional healthcare companies — whether healthcare providers, payers, technology partners or pharmaceutical companies — recognize generative AI’s potential. That potential can manifest in the form of faster drug discovery, more accurate diagnostic tools, improved clinical care and patient services, and so on. Each stakeholder is seeking ways to use the technology to their advantage. Medical professionals, patients and regulators are reacting to this new reality, pondering its implications — both promising and troubling — as well as yet-unanswered ethical questions. Health tech and Big Tech join forces on generative AI solutions. Today, traditional health IT and health-tech companies are partnering with tech giants such as Google, Amazon, Microsoft and Meta to bring their generative AI solutions to life. Leading health IT provider Epic’s partnership with Microsoft to integrate generative AI into its electronic health record (EHR) software is a notable example. The takeaway for both industry stakeholders and generative AI users is to watch investor actions. Sustained investor interest will drive the development of stronger, more effective use cases and lead to the emergence of numerous industry- specific generative AI applications in the years ahead. This trend mirrors the introduction of new technologies in previous decades. Startups set the stage for generative AI in healthcare. The generative AI market for healthcare is valued at more than $1 billion as of 2022, and it is projected to swell to almost $22 billion by 2032. Technology giants along with venture capitalists and private equity investors will play a significant role in that market as investors, partners and innovators. These investments stand to benefit tech startups like Abridge, which is working to integrate its generative AI medical note-taking tool with Epic, a move that promises to streamline clinical workflows. Similarly, startup company Basys.ai secured $2.4 million in seed funding to advance its prior authorization tool, which leverages generative AI and deep learning to expedite the insurance preapproval process for medical procedures. Doctors and patients must have a say in shaping generative AI’s role in clinical settings. For every claim of generative AI’s promise made by technology developers, there is often a fear of the unknown held by nearly everyone else, from medical professionals and patients to government officials. Medical professionals can play a crucial role in demystifying that unknown, especially for their patients. As the experts in care, they have earned patients’ trust through decades of experience and will be responsible for using generative AI in the clinical setting. Patients also must be part of the equation because, after all, it is their health that is at stake. Their fears, comfort levels, trust and consent are factors in determining whether and to what extent generative AI should be involved in their treatment.The post AI Shifts Into the Next (Generative) Gear in Healthcare first appeared on PYMNTS.com.
The post Analyzing the Effect of Approval of Ethereum ETF on Solana: Market Trends and Price Prediction appeared first on Coinpedia Fintech News The news …
Analyzing the Effect of Approval of Ethereum ETF on Solana: Market Trends and Price Prediction
Blockchain · Denaro elettronico
Riepilogo
The post Analyzing the Effect of Approval of Ethereum ETF on Solana: Market Trends and Price Prediction appeared first on Coinpedia Fintech News The news of the approval of Ethereum ETFs by the U.S. Securities and Exchange Commission has influenced the cryptocurrency market immensely, particularly affecting Solana. Within this regulatory change, market experts indicate the rapidly changing dynamics and what it means for Solana investors. Solana’s Potential for an ETF With the approval of the Ethereum ETF by the US SEC, the question of whether Solana might also have an ETF emerges. Borovik, an observer on social platform X, indicated that the same similarities exist between Ethereum and Solana, to imply possibly a future route for the ETF of Solana. Ethereum getting a spot ETF literally means that Solana can get one also– both held an ICO– They both do the same thing– they are both used in the same wayI bet Solana gets an ETF during Trumps term— borovik (@3orovik) May 23, 2024 Anthony Scaramucci, the cofounder of SkyBridge Capital, shares a similar view that a SOL ETF will be announced in the future, citing the importance of Solana in the crypto space. Regulatory Hurdles and Market Response While some experts are optimistic about the possibility of a SOL ETF, regulatory difficulties will have to be overcome. Solana, being an altcoin, is under the radar of the SEC as it is considered an unregistered security. While the SEC has allowed Bitcoin and Ethereum to be considered commodities, Solana has no such recognition. Its recent approval of the spot ETF of Ethereum would underscore this regulatory complexity and subsequently Solana’s short-term price movement. Solana’s Price Volatility Amid Market Dynamics Following the Ethereum ETF approval, Solana has seen significant price movements. Its price dipped to a 7-day low following Ethereum’s market dominance and as the market became cautious. Observers note that there exists a connection between regulatory acceptance of Ethereum and price volatility in Solana, which indicates that major cryptocurrencies are in a correlated response to regulatory shifts. Recent staking trends have been reflective of a more cautious approach from Solana investors and node validators. As Ethereum ETFs continue to attract the attention of institutions, Solana stakeholders pulled out substantial amounts of SOL from staking contracts, possibly fearful of market uncertainties. This amount of unstaking reflects investors’ fears over the bearish impact it could have on the price trajectory of Solana. Price Forecast and Market Outlook In spite of Solana’s bounce above key support levels, sentiment in the futures markets remains bearish. Short traders dominate the scene, betting that SOL price would fail to break past key resistance levels. With significant leverage SHORT positions in play, Solana will find it hard to sustain a price uptrend in the near term. Key resistance areas and psychological support levels are telling insights into Solana’s short-term price movements amidst evolving market dynamics.
HSBC today announced the inauguration of its new U.S. headquarters at The Spiral, a renowned office building in New York City’s Hudson Yards neighborhood,…
HSBC today announced the inauguration of its new U.S. headquarters at The Spiral, a renowned office building in New York City’s Hudson Yards neighborhood, marking its largest U.S. relocation to date.
On the latest episode of Hashing It Out, Avail’s co-founder explains the need to unify multiple networks in the Web3 space, not just ideologically but thr…
Hashing It Out: Navigating the next wave of Web3 with Avail’s Anurag Arjun
Denaro elettronico
Riepilogo
On the latest episode of Hashing It Out, Avail’s co-founder explains the need to unify multiple networks in the Web3 space, not just ideologically but through innovation.